Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tibremciclib (BPI-16350) + Fulvestrant in HR+/HER2- Advanced Breast Cancer
NCT05433480Phase 3Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- May 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tibremciclib in Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative), sponsored by Betta Pharmaceuticals. Status: unknown.
02
Drugs
tibremciclib
03
Conditions
Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative)
Beyond the preview
Go deeper on NCT05433480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05433480.